Cann Group Limited (ASX: CAN) has been granted import permits by the drug control section of the Therapeutic Goods Administration (TGA) that enables the company to commence the import of genetics and cannabis oils from its Canadian partners.
The receipt of the genetics import permits will see Cann begin importing tissue culture from Aurora Cannabis and Anandia Labs, which will be used to develop mother plants for Cann’s cultivation activities.
The importation of these genetics will allow Cann to establish a bank of various genetics, therefore facilitating research into the suitability of each genetic strain for certain therapeutic applications.
In addition, by fostering a plant breeding program Cann will establish surety around the supply of material moving forward and broaden this supply beyond locally available gene banks.
Cann Group has immediately commenced the process to import the tissue culture, which will be received in the coming weeks pending a quarantine screening process conducted by the Department of Agriculture and Water Resources.
The import permits for cannabis oil will allow Cann to bring four products developed by Aurora Cannabis to Australia, which will be made available to medical practitioners seeking to provide medicinal cannabis to patients under the Special Access Scheme or Authorised Prescriber Scheme.
In respect of both sets of permits, the corresponding export permits from Health Canada have also been secured.
Cann Group CEO Peter Crock said working closely with quality Canadian partners enables the Company to more quickly advance its own development.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.